New roles for the major human 3′-5′ exonuclease TREX1 in human disease

Cell Cycle

Volumn 7, Issue 12, 2008, Pages 1718-1725

  Kavanagh, David ^a   Spitzer, Dirk ^b   Kothari, Parul H ^b   Shaikh, Aisha ^b   Liszewski, M Kathryn ^b   Richards, Anna ^c   Atkinson, John P ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cerebrovascular disease; DNase III; Stroke; TREX1; TREX2

Indexed keywords

DEOXYRIBONUCLEASE; EXODEOXYRIBONUCLEASE III; EXODEOXYRIBONUCLEASE V; EXONUCLEASE; EXONUMCLEASE TREX1;

AICARDI GOUTIERES SYNDROME; ARTICLE; CEREBRAL LEUKODYSTROPHY; CEREBRORETINAL VASCULOPATHY; CHROMOSOME 3P; CYTOLOGY; DNA REPLICATION; DNA SYNTHESIS; ENZYME ACTIVITY; FAMILIAL CHILBLAIN LUPUS; GENE; GENE MAPPING; GENE MUTATION; GENE STRUCTURE; GENETIC ANALYSIS; GENETICS; HETEROZYGOSITY; LEUKODYSTROPHY; LUPUS ERYTHEMATOSUS; MITOSIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREX1 GENE; VASCULAR DISEASE;

EID: 47249142894     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.12.6162     Document Type: Article

References (78)

1. Ophoff RA, DeYoung J, Service SK, et al. Hereditary vascular retinopathy, cerebroretinal vasculopathy and hereditary endotheliopathy with retinopathy, nephropathy and stroke map to a single locus on chromosome 3p21.1-p21.3. Am J Hum Genet 2001; 69:447-53.
2. Richards A, van den Maagdenberg AM, Jen JC, et al. Truncations in the carboxyl-terminus of human 3′-5′ DNA exonuclear TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007; 39:1068-70.
3. Crow YJ, Hayward BE, Parmar R, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet 2006; 38:917-20.
4. Lee-Kirsch MA, Gong M, Schulz H, et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 2006; 79:731-7.
5. Rice G, Newman WG, Dean J, et al. Heterozygous mutations in TREX1 cause familial Chilblain lupus and dominant Aicardi-Goutieres syndrome. Am J Hum Genet 2007; 80:811-5.
6. Lee-Kirsch MA, Gong M, Chowdhury D, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007; 39:1065-7.
7. Hubscher U, Maga G, Spadari S. Eukaryotic DNA polymerases. Annu Rev Biochem 2002; 71:133-63.
8. Lindahl T, Gally JA, Edelman GM. Properties of deoxyribonuclease 3 from mammalian tissues. J Biol Chem 1969; 244:5014-9.
9. Shevelev IV, Hubscher U. The 3′-5′ exonucleases. Nat Rev Mol Cell Biol 2002; 3:364-76.
10. Drake JW, Charlesworth B, Charlesworth D, Crow JF. Rates of spontaneous mutation. Genetics 1998; 148:1667-86.
11. Lindahl T. Excision of pyrimidine dimers from ultraviolet-irradiated DNA by exonucleases from mammalian cells. Eur J Biochem 1971; 18:407-14.
12. Hoss M, Robins P, Naven TJ, Pappin DJ, Sgouros J, Lindahl T. A human DNA editing enzyme homologous to the Escherichia coli DnaQ/MutD protein. EMBO J 1999; 18:3868-75.
13. Mazur DJ, Perrino FW. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3′→5′ exonucleases. J Biol Chem 1999; 274:19655-60.
14. Barnes MH, Spacciapoli P, Li DH, Brown NC. The 3′-5′ exonuclease site of DNA polymerase III from gram-positive bacteria: definition of a novel motif structure. Gene 1995; 165:45-50.
15. Strauss BS, Sagher D, Acharya S. Role of proofreading and mismatch repair in maintaining the stability of nucleotide repeats in DNA. Nucleic Acids Res 1997; 25:806-13.
16. Taft-Benz SA, Schaaper RM. Mutational analysis of the 3′→5′ proofreading exonuclease of Escherichia coli DNA polymerase III. Nucleic Acids Res 1998; 26:4005-11.
17. de Silva U, Choudhury S, Bailey SL, Harvey S, Perrino FW, Hollis T. The crystal structure of TREX1 explains the 3′ nucleotide specificity and reveals a polyproline II helix for protein partnering. J Biol Chem 2007; 282:10537-43.
18. Brucet M, Querol-Audi J, Serra M, et al. Structure of the dimeric exonuclease TREX1 in complex with DNA displays a proline-rich binding site for WW domains. J Biol Chem 2007.
19. Zarrinpar A, Bhattacharyya RP, Lim WA. The structure and function of proline recognition domains. Sci STKE 2003; 2003:8.
20. Bebenek K, Matsuda T, Masutani C, Hanaoka F, Kunkel TA. Proofreading of DNA polymerase eta-dependent replication errors. J Biol Chem 2001; 276:2317-20.
21. Mazur DJ, Perrino FW. Structure and expression of the TREX1 and TREX2 3′→5′ exonuclease genes. J Biol Chem 2001; 276:14718-27.
22. Morita M, Stamp G, Robins P, et al. Gene-targeted mice lacking the Trex1 (DNase III) 3′→5′ DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 2004; 24:6719-27.
23. Chowdhury D, Beresford PJ, Zhu P, et al. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell 2006; 23:133-42.
24. Yang YG, Lindahl T, Barnes DE. Trex1 Exonuclease Degrades ssDNA to Prevent Chronic Checkpoint Activation and Autoimmune Disease. Cell 2007; 131:873-86.
25. Coscoy L, Raulet DH. DNA mismanagement leads to immune system oversight. Cell 2007; 131:836-8.
26. Chen MJ, Ma SM, Dumitrache LC, Hasty P. Biochemical and cellular characteristics of the 3′→5′ exonuclease TREX2. Nucleic Acids Res 2007; 35:2682-94.
27. Aicardi J, Goutieres F. A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 1984; 15:49-54.
28. Goutieres F. Aicardi-Goutieres syndrome. Brain Dev 2005; 27:201-6.
29. Goutieres F, Aicardi J, Barth PG, Lebon P. Aicardi-Goutieres syndrome: an update and results of interferon-alpha studies. Ann Neurol 1998; 44:900-7.
30. Burn J, Wickramasinghe HT, Harding B, Baraitser M. A syndrome with intracranial calcification and microcephaly in two sibs, resembling intrauterine infection. Clin Genet 1986; 30:112-6.
31. Reardon W, Hockey A, Silberstein P, et al. Autosomal recessive congenital intrauterine infecction-like syndrome of microcephaly, intracranial calcification and CNS disease. American Journal Medical Genetics 1994; 52:58-65.
32. Black DN, Watters GV, Andermann E, et al. Encephalitis among Cree children in northern Quebec. J Med Genet 1988; 40:183-7.
33. Sanchis A, Cervero L, Bataller A, et al. Genetic syndromes mimic congenital infections. J Pediatr 2005; 146:701-5.
34. Crow YJ, Black DN, Ali M, et al. Cree encephalitis is allelic with Aicardi-Goutieres syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism. J Med Genet 2003; 40:183-7.
35. Dale RC, Tang SP, Heckmatt JZ, Tatnall FM. Familial systemic lupus erythematosus and congenital infection-like syndrome. Neuropediatrics 2000; 31:155-8.
36. Rasmussen M, Skullerud K, Bakke SJ, Lebon P, Jahnsen FL. Cerebral thrombotic microangiopathy and antiphospholipid antibodies in Aicardi-Goutieres syndrome - report of two sisters. Neuropediatrics 2005; 36:40-4.
37. De Laet C, Goyens P, Christophe C, Ferster A, Mascart F, Dan B. Phenotypic overlap between infantile systemic lupus erythematosus and Aicardi-Goutieres syndrome. Neuropediatrics 2005; 36:399-402.
38. Lebon P, Lenoir GR, Fischer A, Lagrue A. Synthesis of intrathecal interferon in systemic lupus erythematosus with neurological complications. Br Med J (Clin Res Ed) 1983; 287:1165-7.
39. Crow YJ, Leitch A, Hayward BE, et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nat Genet 2006; 38:910-6.
40. Frank P, Braunshofer-Reiter C, Wintersberger U, Grimm R, Busen W. Cloning of the cDNA encoding the large subunit of human RNase HI, a homologue of the prokaryotic RNase HII. Proc Natl Acad Sci USA 1998; 95:12872-7.
41. Eder PS, Walder JA. Ribonuclease H from K562 human erythroleukemia cells. Purification, characterization and substrate specificity. J Biol Chem 1991; 266:6472-9.
42. Rice G, Patrick T, Parmar R, et al. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. American Journal of Human Genetics 2007; 81:713-25.
43. Lee-Kirsch MA, Chowdhury D, Harvey S, et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med 2007; 85:531-7.
44. Millard LG, Rowell NR. Chilblain lupus erythematosus (Hutchinson). A clinical and laboratory study of 17 patients. Br J Dermatol 1978; 98:497-506.
45. Grand MG, Kaine J, Fulling K, et al. Cerebroretinal vasculopathy: A new hereditary syndrome. Ophthalmology 1988; 95:649-59.
46. Gutmann DH, Fischbeck KH, Sergott RC. Hereditary retinal vasculopathy with cerebral white matter lesions. Am J Med Genet 1989; 34:217-20.
47. Weil S, Reifenberger G, Dudel C, Yousry TA, Schriever S, Noachtar S. Cerebroretinal vasculopathy mimicking a brain tumor: a case of a rare hereditary syndrome. Neurology 1999; 53:629-31.
48. Niedermayer I, Graf N, Schmidbauer J, Reiche W. Cerebroretinal vasculopathy mimicking a brain tumor. Neurology 2000; 54:1878-9.
49. Storimans CW, Oosterhuis JA, van Schooneveld MJ, Bos PJ, Maaswinkel-Mooy PD. Familial vascular retinopathy. A preliminary report. Doc Ophthalmol 1990; 75:259-61.
50. Terwindt GM, Haan J, Ophoff RA, et al. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon. Brain 1998; 121:303-16.
51. Jen J, Cohen AH, Yue Q, et al. Hereditary endotheliopathy with retinopathy, nephropathy and stroke (HERNS). Neurology 1997; 49:1322-30.
52. Cohn AC, Kotschet K, Veitch A, Delatycki MB, McCombe MF. Novel ophthalmological features in hereditary endotheliopathy with retinopathy, nephropathy and stroke syndrome. Clinical & Experimental Ophthalmology 2005; 33:181-3.
53. Winkler DT, Lyrer P, Probst A, et al. Hereditary Systemic Angiopathy (HSA) with cerebral calcifications, retinopathy, progressive nephropathy and hepatopathy. J Neurol 2008; 255:77-88.
54. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929-39.
55. Crow MK. Collaborations, genetic associations and lupus erythematosus. N Engl J Med 2008; 358:956-61.
56. Hur JW, Sung YK, Shin HD, Park BL, Cheong HS, Bae SC. TREX1 polymorphisms associated with autoantibodies in patients with systemic lupus erythematosus. Rheumatol Int 2007.
57. Unterholzner L, Bowie AG. The interplay between viruses and innate immune signaling: recent insights and therapeutic opportunities. Biochem Pharmacol 2008; 75:589-602.
58. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301:5-8.
59. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9:664-71.
60. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005; 64:1692-7.
61. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferonalpha. Autoimmunity 2003; 36:511-8.
62. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115:178-83.
63. Heremans H, Billiau A, Colombatti A, Hilgers J, de Somer P. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immun 1978; 21:925-30.
64. Adam C, Thoua Y, Ronco P, Verroust P, Tovey M, Morel-Maroger L. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin Exp Immunol 1980; 40:373-82.
65. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFNalpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 2005; 174:2499-506.
66. Walker SE. Accelerated mortality in young NZB/NZW mice treated with the interferon inducer tilorone hydrochloride. Clin Immunol Immunopathol 1977; 8:204-12.
67. Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197:777-88.
68. Braun D, Geraldes P, Demengeot J. Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003; 20:15-25.
69. Akwa Y, Hassett DE, Eloranta ML, et al. Transgenic expression of IFNalpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol 1998; 161:5016-26.
70. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111:350-6.
71. Sugano S, Yanagimoto M, Suzuki T, et al. Retinal complications with elevated circulating plasma C5a associated with interferon-alpha therapy for chronic active hepatitis C. Am J Gastroenterol 1994; 89:2054-6.
72. Hayasaka S, Fujii M, Yamamoto Y, Noda S, Kurome H, Sasaki M. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol 1995; 79:150-2.
73. Soushi S, Kobayashi F, Obazawa H, et al. [Evaluation of risk factors of interferon-associated retinopathy in patients with type C chronic active hepatitis]. Nippon Ganka Gakkai Zasshi 1996; 100:69-76.
74. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91:309-13.
75. Lebon P. Inhibition of herpes simplex virus type 1-induced interferon synthesis by monoclonal antibodies against viral glycoprotein D and by lysosomotropic drugs. J Gen Virol 1985; 66:2781-6.
76. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197:711-23.
77. Chuntharapai A, Lai J, Huang X, et al. Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: a candidate therapeutic for IDDM and SLE. Cytokine 2001; 15:250-60.
78. Han CS, Chen Y, Ezashi T, Roberts RM. Antiviral activities of the soluble extracellular domains of type I interferon receptors. Proc Natl Acad Sci USA 2001; 98:6138-43.